查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1138337

富血小板血浆 (PRP)-2022-2029 的全球市场

Global Platelet Rich Plasma Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

新的富血小板血浆 (PRP) 疗法可用于各种应用，预计将推动市场增长。

富血小板血浆疗法被认为是治疗和治疗的绝佳新选择。由于在整容手术中的应用越来越多，富血小板血浆疗法最近已广泛用于临床环境。皮肤科医生和整形外科医生还利用富含血小板的血浆的自然癒合能力来改善皮肤的外观和健康。它也用于面部年轻化，其效果可期。还使用纯富含血小板的血浆，因为它具有更快的组织形成和修復、更快的癒合和更好的整体性能等优点。此外，由于副作用小、免疫和过敏反应风险低，预计血小板减少血浆市场将迅速上升。因此，上述声明预计将在预测期内推动市场。

限制

富血小板血浆疗法价格波动大，伤口护理设备报销政策优惠。此外，质量控制问题、实验室检查结果以及与富含血小板的血浆疗法相关的缺陷会导致治疗部位的神经损伤、组织损伤和感染。因此，预计上述陈述将在预测期内阻碍市场。

COVID-19 影响分析

COVID-19 大流行对市场产生了积极影响。没有特定的抗病毒药物可用于治疗。在 2019 年冠状病毒病 (COVID-19) 中经常观察到血栓栓塞的并发症。另一方面，COVID-19 与血小板失调有关。 COVID-19 的不良后果与基础血小板活化增加和血小板反应降低有关，随着时间的推移，这种情况会恶化。随着 COVID-19 的爆发，对富血小板血浆疗法的需求显着增加，因为血小板在消除呼吸系统疾病和维持肺功能方面发挥着重要作用，因此将富血小板血浆疗法用于冠状病毒治疗。例如，作为适应性免疫疗法的代表的恢復期血浆（CP）疗法已被应用于预防和治疗多种传染病一个多世纪。在过去的二十年里，CP 疗法成功地治疗了 SARS、MERS 和 2009 年 H1N1 大流行，具有令人满意的疗效和安全性。因此，这是为了在预测期内提振富含血小板的血浆市场。

行业分析

富含血小板的血浆市场根据各种行业因素（例如未满足的需求、定价分析、供应链分析和监管分析）对市场进行深入分析。

全球富血小板血浆市场报告包含大约 45 多个市场数据表、40 多个数字和 180 页。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按类型划分的市场细分
  • 按应用划分的市场细分
  • 按产地划分的市场细分
  • 最终用户的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 由于富血小板血浆 (PRP) 疗法的兴起，该市场有望增长，该疗法用于各种应用。
    • 约束因素
      • 与富含血小板的血浆相关的缺点预计会阻碍市场增长。
    • 机会
    • 影响分析

第五章行业分析

  • 供应链分析
  • 定价分析
  • 法律法规分析
  • 未满足的需求

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按类型

  • 富含血小板的纯血浆
  • 白细胞增多型PRP
  • 富含白细胞的纤维蛋白
  • 其他

第 8 章按应用程序

  • 骨科
  • 美容外科/皮肤科
  • 神经内科
  • 循环区
  • 眼科
  • 其他

第 9 章按原产地

  • 自体 PRP
  • 自体 PRP
  • 异基因 PRP
  • 其他

第 10 章，最终用户

  • 医院
  • 诊所
  • 其他

第 11 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 12 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准
  • 值得关注的重点公司列表

第 13 章全球富血小板血浆市场 - 公司简介

  • Zimmer Biomet
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Johnson & Johnson（DePuy Synthes）
  • Arthrex Inc.
  • Terumo BCT Inc.
  • Celling BioSciences
  • APEX Biologix
  • Juventix
  • Dr. PRP America
  • Stryker
  • Ycellbio Medical Co., Ltd (*未详尽列出)

第 14 章数据M

简介目录
Product Code: DMMD1333

Market Overview

Platelet Rich Plasma Market is expected to grow at a CAGR of 13.88% during the forecasting period (2022-2029).

Platelet-rich plasma (PRP) is derived from blood. It's made when human blood is spun down and platelet-rich plasma, which has a higher concentration of platelets than normal, is extracted. Platelets assist in blood clotting and assist tendons, muscles, and ligaments repair faster. PRP is used in various operations, including rotator cuff augmentation and tendon repair. Healing factors and connective tissue development is abundant in platelets.

Market Dynamics

Emerging platelet-rich plasma (PRP) therapy utilized for various applications is expected to drive market growth.

Platelet-rich plasma therapy is considered a superior emerging choice for therapy and procedures. Platelet-rich plasma therapy has recently been widely used in clinical settings, owing to increased use in cosmetic operations. In addition, dermatologists and plastic surgeons use platelet-rich plasma's natural healing qualities to improve the appearance and health of the skin. Its usage in face rejuvenation has also yielded promising effects. Pure platelet-rich plasma is also used because of its benefits, such as faster tissue formation and repair, faster healing, and greater overall performance. Also, with fewer side effects and a lower risk of immunological reaction and allergic reactions, the Platelet Rich Plasma market is expected to rise rapidly. Thus, the market is expected to drive in the forecast period from the above statements.

Restraint:

There is high price variability in platelet-rich plasma therapy and favorable reimbursement policies in wound care equipment. Furthermore, issues with quality control and test findings and drawbacks associated with platelet-rich plasma therapy induce nerve damage, tissue damage, and infection in the treatment region. Therefore, the market is expected to get hampered in the forecast period from the above statements.

COVID-19 Impact Analysis

The COVID-19 pandemic had a positive impact on the market. There are no specific antiviral agents available for its treatment. Thromboembolic complications are frequently observed in Coronavirus disease 2019 (COVID-19). In contrast, COVID-19 is linked to platelet dysregulation. An adverse outcome in COVID-19 was associated with increased basal platelet activation and diminished platelet responses, which aggravated over time. Due to the covid-19 outbreak, platelet-rich plasma therapy was used to treat coronavirus as platelets play a vital role in eliminating respiratory disorders and maintaining the functioning of the lungs due to the demand for platelet-rich plasma therapy has significantly increased. For instance, Convalescent plasma (CP) therapy, classic adaptive immunotherapy, has been applied to prevent and treat many infectious diseases for more than one century. Over the past two decades, CP therapy successfully treated SARS, MERS, and the 2009 H1N1 pandemic with satisfactory efficacy and safety. Thus, this is due to boosting the forecast period's platelet-rich plasma market.

Industry Analysis

The platelet rich plasma market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

Segment Analysis

Pure Platelet Rich Plasma segment is expected to hold the largest market share in the platelet-rich plasma market.

The pure platelet-rich plasma segment accounted for the largest market share in 2021. The segment benefits because it has rapid healing, tissue repair and production, and general function improvement, which have enhanced its demand across several treatment business spaces, adding to segment expansion. In pure PRP therapeutic approaches, entities in the market are paying attention to effectively eliminating dangers and unwanted effects, such as allergic or immunological reactions. PRP's present off-label use has prompted numerous manufacturers worldwide to produce various sorts of products, owing to its tremendous promise in treating various chronic illnesses. For instance, Celling Biosciences is dedicated to the scientific understanding and therapeutic application of autologous cell therapy, which includes ART PRP product which is widely used in orthopedic and sports medicine to relieve pain through the natural promotion of healing in musculoskeletal diseases such as tendonitis, arthritis, ligament sprains, and tears. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.

Geographical Analysis

North American region is expected to hold the largest market share in the global platelet rich plasma market.

In 2021, North America accounted for the highest revenue share. The increasing number of cosmetic surgeries, high awareness about platelet-rich plasma-based treatments, technological advancement, well-established infrastructure, product launches and approvals by the market players are some factors that the market is expected to boost in the forecast period. For instance, with approximately four million cosmetic treatments performed in 2020, the United States will have the highest number of cosmetic procedures globally. Over the last decade, the number of surgical and nonsurgical cosmetic treatments performed in the United States has increased, from over 1.6 million in 1997 to over 5.5 million in 2020. Moreover, EmCyte acquired Cellmedix Holdings LLC in February 2020, acquiring all of the latter's assets, including its proprietary product system, the Centrepid Platelet Concentrator. EmCyte's product development skills and intellectual property profile will be enhanced as a result of this strategic purchase. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Competitive Landscape

Major key players in the platelet-rich plasma market are Zimmer Biomet, Johnson & Johnson (DePuy Synthes), Arthrex Inc., Terumo BCT Inc., Celling BioSciences , APEX Biologix, Juventix, Dr. PRP America, Stryker and Ycellbio Medical Co., Ltd.

Johnson & Johnson (DePuy Synthes):

Overview:

Johnson & Johnson (DePuy Synthes) designs, manufacture, and markets various orthopedic and neurological devices globally. The company is involved in developing medical devices for diagnosing damaged joints and repairing reconstructing skeletal injuries. It has a comprehensive portfolio of orthopedic products and neuro products, and it focuses on the therapeutic areas of spinal care, orthopedics, sports medicine, and neurosciences. It offers products, services, programs, and R&D capabilities to advance patient care and adds clinical and economic value to healthcare systems. In many countries, the company operates under the name of Johnson and Johnson.

Product Portfolio:

PEAK Platelet Rich Plasma System: The PEAK Platelet Rich Plasma System represents an option in autologous cellular therapies featuring a vertical roto centrifugation process. The proprietary technology consistently delivers 3 ml of 7.8x high-concentration platelet rich plasma (PRP) from 27 ml of whole blood within 2.5 minutes.

The global Platelet rich plasma market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by Origin
  • 3.4. Market Snippet by End User
  • 3.5. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Emerging platelet-rich plasma (PRP) therapy utilized for various applications is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. The drawbacks associated with platelet-rich plasma are expected to hamper market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Pure Platelet Rich Plasma*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Leukocyte Rich PRP
  • 7.4. Leukocyte-Rich Fibrin
  • 7.5. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application Segment
  • 8.2. Orthopedics*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Cosmetic Surgery and Dermatology
  • 8.4. Neurology
  • 8.5. Cardiology
  • 8.6. Ophthalmology
  • 8.7. Others

9. By Origin

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Origin
    • 9.1.2. Market Attractiveness Index, By Origin Segment
  • 9.2. Autologous PRP*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Homologous PRP
  • 9.4. Allogeneic PRP
  • 9.5. Others

10. By End user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.1.2. Market Attractiveness Index, By End user Segment
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 10.3. Clinics
  • 10.4. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Origin
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Origin
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Origin
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Origin
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Origin
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. List of Key Companies to Watch

13. Global Platelet-rich Plasma Market- Company Profiles

  • 13.1. Zimmer Biomet*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Johnson & Johnson (DePuy Synthes)
  • 13.3. Arthrex Inc.
  • 13.4. Terumo BCT Inc.
  • 13.5. Celling BioSciences
  • 13.6. APEX Biologix
  • 13.7. Juventix
  • 13.8. Dr. PRP America
  • 13.9. Stryker
  • 13.10. Ycellbio Medical Co., Ltd(*LIST NOT EXHAUSTIVE)

14. DataM Intelligence

  • 14.1. Appendix
  • 14.2. About Us and Applications
  • 14.3. Contact Us